Stocks · News reference
SciSparc Unit Neurothera Labs And Clearmind Medicine Publish U.S. Patent Application For A Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines For Use In Methods Of Treating Post-Traumatic Stress Disorder, Anxiety And Eating Disorders
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Clearmind Medicine Stock Slides Friday: What's Happening?
Clearmind Medicine shares are trading lower Friday as investors weigh the biotech’s move to acquire a majority stake in an EV charging firm.
Clearmind Medicine Announces $2.5M Deal To Acquire 51% Stake In EV Wireless Charging Firm Charging Robotics, Plus $1.5M Loan At 4%; Expects Close Week Of September 7
Clearmind Medicine Initiates Phase lla, Double-Blind, Placebo-Controlled Phase I/IIa Clinical Trial Evaluating CMND-100 For Treatment Of AUD
Clearmind Medicine Inc. (NASDAQ:CMND) (the "Company"), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric,
SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation Covering SCI-110
This strategic engagement is designed to strengthen NeuroThera’s U.S. market position, visibility among key U.S. federal stakeholders, reinforce the clinical and public‑health importance of advancing new treatment
SciSparc shares are trading higher after the company announced its subsidiary, NeuroThera labs, continued advancement in participant enrollment for the clinical trial assessing the SCI-210 treatment for symptoms associated with autism spectrum disorder